Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

State-of-the-art in the treatment of chronic myeloid leukaemia.

Current opinion in oncology - 1 Jan 2008

Milojkovic Dragana, Apperley Jane

Abstract excerpt

PURPOSE OF REVIEW: To revise the current goals of therapy of chronic myeloid leukaemia and to incorporate the influence of the underlying chronic myeloid leukaemia biology on directing therapeutic management. RECENT FINDINGS: The management of chronic myeloid leukaemia has been revolutionized by targeted molecular therapy that inhibits the ABL kinase activity of the BCR-ABL gene. The achievement of a major...

Topics

Join the communities discussing this publication.

Benzamides
Fusion Proteins, bcr-abl
Genes, abl
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Transplantation, Homologous

Source

Identifiers

PMID: 18043265
DOI: 10.1097/CCO.0b013e3282f1fe8a

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

State-of-the-art in the treatment of chronic myeloid leukaemia.PMID 18043265Read ↗

Therapeutic targets in chronic myeloid leukaemiaSemantic proximity Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.Semantic proximity Read ↗

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringSemantic proximity Read ↗

Natural course and biology of CML.Semantic proximity Read ↗

Molecular and cellular bases of chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.